CA
NZ
UK
AU
IND
US
…
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -18.59M | -24.22M | -31.25M | -17.05M | -17.82M |
| Minority interest | 0.00M | 0.00M | 0.00M | -0.03M | -0.03M |
| Net income | -17.03M | -22.70M | -33.53M | -21.43M | -17.79M |
| Selling general administrative | 0.01M | 7.24M | 7.15M | 4.02M | 6.59M |
| Selling and marketing expenses | 4.68M | - | - | - | - |
| Gross profit | -0.80M | -0.48M | -0.31M | -0.28M | -0.26M |
| Reconciled depreciation | 0.80M | 0.48M | 0.31M | 0.28M | 0.26M |
| Ebit | -15.89M | -23.27M | -26.82M | -13.94M | -15.68M |
| Ebitda | -15.09M | -23.66M | -26.50M | -14.23M | -15.75M |
| Depreciation and amortization | 0.80M | -0.38M | 0.31M | -0.28M | -0.07M |
| Operating income | -15.89M | -23.27M | -26.82M | -13.94M | -15.68M |
| Other operating expenses | 15.89M | 23.27M | 26.82M | 13.94M | 15.68M |
| Interest expense | 1.25M | 1.60M | 4.43M | 4.37M | 2.53M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | -0.03M |
| Net interest income | -1.41M | -2.46M | -4.43M | -4.94M | -2.86M |
| Income tax expense | -1.56M | -1.52M | 2.28M | 4.37M | -0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 15.09M | 23.27M | 26.82M | 13.94M | 15.68M |
| Cost of revenue | 0.80M | 0.48M | 0.31M | 0.28M | 0.26M |
| Total other income expense net | -2.69M | -0.94M | -4.43M | -3.11M | -2.13M |
| Net income from continuing ops | -17.03M | -24.22M | -31.25M | -17.05M | -17.79M |
| Net income applicable to common shares | - | -24.22M | -31.25M | -17.05M | -17.79M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11.94M | 21.99M | 36.26M | 27.21M | 17.67M |
| Intangible assets | 2.64M | 2.65M | 2.76M | 2.67M | 2.40M |
| Other current assets | 0.84M | -0.00M | 1.42M | -0.00M | -0.00M |
| Total liab | 15.85M | 23.90M | 30.56M | 20.38M | 25.20M |
| Total stockholder equity | -3.88M | -1.88M | 5.74M | 6.86M | -7.50M |
| Other current liab | 1.77M | 4.47M | 6.28M | 3.11M | 0.45M |
| Common stock | 2.08M | 47.66M | 27.19M | 20.15M | 4.79M |
| Capital stock | 2.08M | 47.66M | 27.19M | 20.15M | 4.79M |
| Retained earnings | -19.38M | -47.91M | -49.11M | -17.05M | -17.79M |
| Other liab | - | 0.18M | 1.12M | 0.19M | 0.14M |
| Other assets | 0.00M | 0.17M | 1.25M | 0.40M | 0.36M |
| Cash | 5.57M | 11.05M | 23.93M | 5.85M | 6.34M |
| Total current liabilities | 12.37M | 19.35M | 23.14M | 18.36M | 19.66M |
| Current deferred revenue | 0.18M | 0.18M | 0.17M | - | 1.50M |
| Net debt | 2.70M | 1.07M | -8.55M | 3.25M | 8.91M |
| Short term debt | 5.02M | 7.76M | 9.08M | 7.26M | 9.85M |
| Short long term debt | 3.47M | 7.48M | 8.86M | 7.26M | 9.85M |
| Short long term debt total | 8.27M | 12.13M | 15.38M | 9.10M | 15.24M |
| Other stockholder equity | 13.45M | -1.61M | 27.73M | 17.78M | 45.22M |
| Property plant equipment | - | 0.58M | 0.56M | 0.11M | 0.18M |
| Total current assets | 8.85M | 18.58M | 31.69M | 24.01M | 14.71M |
| Long term investments | 0.03M | 0.05M | 0.08M | 0.09M | 0.04M |
| Net tangible assets | - | -4.53M | 2.98M | 4.19M | -9.89M |
| Short term investments | 0.37M | 0.59M | 1.23M | 12.92M | 0.47M |
| Net receivables | 2.44M | 5.36M | 5.12M | 5.21M | 7.85M |
| Long term debt | 2.42M | 4.18M | 6.07M | 1.83M | 5.40M |
| Inventory | - | 1.57M | - | 0.03M | 0.05M |
| Accounts payable | 5.39M | 6.94M | 7.61M | 7.99M | 7.87M |
| Accumulated other comprehensive income | -0.03M | -0.03M | -0.07M | -14.01M | -39.72M |
| Common stock total equity | - | - | - | 20.15M | 4.79M |
| Non currrent assets other | -0.00M | 0.12M | 1.17M | 0.32M | 0.34M |
| Non current assets total | 3.09M | 3.41M | 4.57M | 3.20M | 2.97M |
| Capital lease obligations | 0.19M | 0.47M | 0.45M | - | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 0.37M | -0.02M | 12.16M | -12.50M | -12.50M |
| Change to liabilities | - | -0.67M | -0.38M | 0.12M | 2.64M |
| Total cashflows from investing activities | - | -0.02M | 12.16M | -12.71M | -0.28M |
| Net borrowings | - | 7.20M | 17.00M | 4.88M | 4.57M |
| Total cash from financing activities | 7.49M | 6.13M | 29.71M | 22.07M | 7.50M |
| Change to operating activities | - | -0.05M | 0.12M | 0.05M | 0.11M |
| Net income | -17.03M | -24.22M | -31.25M | -17.05M | -17.79M |
| Change in cash | -5.49M | -12.87M | 18.08M | -0.49M | -8.07M |
| Begin period cash flow | 11.05M | 23.93M | 5.85M | 6.34M | 14.41M |
| End period cash flow | 5.57M | 11.05M | 23.93M | 5.85M | 6.34M |
| Total cash from operating activities | -13.33M | -18.99M | -23.80M | -9.86M | -15.27M |
| Issuance of capital stock | 5.54M | 0.00M | 16.58M | 23.49M | - |
| Depreciation | 0.80M | 0.48M | 0.31M | 0.28M | 0.26M |
| Other cashflows from investing activities | - | - | 0.00M | 0.00M | 0.00M |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | - | 0.40M | 3.36M | 3.01M | 2.94M |
| Change to account receivables | 1.67M | -0.40M | -3.36M | -3.01M | -2.94M |
| Other cashflows from financing activities | 0.00M | 8.22M | 16.73M | 2.55M | 7.55M |
| Change to netincome | - | 5.26M | 8.46M | 3.90M | 0.06M |
| Capital expenditures | 0.22M | 0.14M | 0.34M | 0.21M | 0.28M |
| Change in working capital | -0.03M | -1.33M | 1.32M | 3.01M | -0.36M |
| Stock based compensation | 0.81M | 5.57M | 3.42M | 0.79M | 0.06M |
| Other non cash items | 4.18M | 0.51M | 0.48M | 4.52M | 3.31M |
| Free cash flow | -13.55M | -19.13M | -24.14M | -10.08M | -15.55M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
| Name | Title | Year Born |
|---|---|---|
| Mr. Stanislas Veillet Ph.D. | Chairman & CEO | 1965 |
| Mr. Philippe J. Rousseau | Chief Financial Officer | 1971 |
| Mr. Waly Dioh | Chief Operating Officer | 1969 |
| Dr. Pierre J. Dilda | Chief Scientific Officer | 1970 |
| Dr. Rene Lafont | Scientific Advisor & Member of Scientific Advisory Board | 1946 |
| Mr. Benoit Canolle | Chief Bus. Officer | 1978 |
| Mr. Rob van Maanen FFPM, M.B.A., M.D. | Chief Medical Officer | 1970 |
| Ms. _ Teylan | Financial Controller | NA |
| Mr. Stanislas Veillet Ph.D. | Chairman of the Board & CEO | 1965 |
| Mr. Nicolas Fellmann | Chief Financial Officer | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...